► My Stock Portfolio + BUY and SELL alerts:
► Subscribe for new videos every day!:
► Early Retirement Blueprint:
► Read it here:

Amgen, Inc. (AMGN) is a global biotechnology company that develops and manufactures a range of human therapeutics.

Founded in 1980, Amgen is now a $113 billion (by market cap) healthcare behemoth that employs more than 24,000 people.

Amgen offers treatments for a range of ailments, including anemia, rheumatoid arthritis, psoriasis, cancer, and osteoporosis.

FY 2020 total product sales break down geographically as follows: US, 74%; Rest of World, 26%.

Some of its major drugs include: Enbrel, 21% of FY 2020 sales; Prolia, 11%; Neulasta, 9%; Otezla, 9%; and XGEVA, 8%.

Their biggest blockbuster, Enbrel, generates over $5 billion in total annual sales and has patent protection until almost the end of this decade.

Amgen is benefiting from a rising tide that is lifting all boats.

Already, Amgen has increased its dividend for 11 consecutive years.

The five-year dividend growth rate is an astounding 15.2%.

That double-digit dividend growth is paired with a starting yield of 3.5%.

This yield is substantially higher than what the broader market offers.

It’s also 80 basis points higher than the stock’s own five-year average yield.

This is a highly appealing combination of yield and growth that I don’t often come across.

And with a payout ratio of only 41.9%, based on midpoint adjusted EPS guidance for this fiscal year, the dividend is in a great position to continue growing at a relatively high rate.

I love dividend growth stocks in what I refer to as the “sweet spot” – that’s a yield of between 2.5% and 3.5%, paired with a high-single-digit (or better) dividend growth rate.

As you can see, this stock is basically as “sweet” as it gets.

Moving over to the balance sheet, Amgen commands a good financial position.

The long-term debt/equity ratio is 3.5.

While that is very high, it’s only so high because of low common equity (not an outrageous debt load).

The interest coverage ratio of over 7 shows no problems with servicing debt.

Profitability is extremely robust.

Over the last five years, the firm has averaged annual net margin of 27.0% and annual return on equity of 46.3%.

There’s almost nothing to dislike about Amgen.

The P/E ratio is 20.7.

That’s better than the broader market’s earnings multiple.

It’s also materially lower than the stock’s own five-year average P/E ratio of 24.6.

We can also see a disconnect on the sales multiple.

The current P/S ratio of 4.5 is well off of its own five-year average of 5.6.

And the yield, as noted earlier, is significantly higher than its own recent historical average.

Morningstar rates AMGN as a 3-star stock, with a fair value estimate of $200.00.

CFRA is another professional analysis firm, and I like to compare my valuation opinion to theirs to see if I’m out of line.

They similarly rate stocks on a 1-5 star scale, with 1 star meaning a stock is a strong sell and 5 stars meaning a stock is a strong buy. 3 stars is a hold.

CFRA rates AMGN as a 4-star “BUY”, with a 12-month target price of $245.00.

I came in surprisingly high, but I’d also argue that Morningstar is too low. Averaging the three numbers out gives us a final valuation of $249.24, which would indicate the stock is possibly 24% undervalued.

Bottom line: Amgen, Inc. (AMGN) is a high-quality company across the board. They benefit from a rising tide lifting all boats. With a market-beating 3.5% yield, double-digit long-term dividend growth, more than 10 consecutive years of dividend increases, a low payout ratio, and the potential that shares are 24% undervalued, this is a world-class healthcare business that is on sale.

► Website:
► Patreon:

#BeatDownStock #UndervaluedStock #CheapStocks $AMGN

LEGAL DISCLAIMER: Please consult with a licensed investment professional before investing any of your money. Never invest in a security or idea featured on this channel unless you can afford to lose your entire investment. If your money is not FDIC insured, it may decline in value. Jason is not a licensed financial advisor, tax professional, or stockbroker and he does not purport to be. The links above may include affiliate commissions paid to the owners of Dividends and Income and help support this channel.


The post Time to Load Up? This Dividend Growth Stock Has Been Beat Down By 30% appeared first on Correct Success.

Reader's opinions

Leave a Reply

Current track